Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [(177)Lu]Lu-PSMA-617 - Ahmadzadehfar, H; Wegen, S; Yordanova, A (EJNMMI, 2017)
et al.